v3.25.2
GENERAL (Narrative) (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended 12 Months Ended
Jul. 08, 2025
USD ($)
Apr. 21, 2025
USD ($)
Aug. 06, 2019
USD ($)
Apr. 17, 2025
USD ($)
Apr. 15, 2025
Aug. 26, 2024
USD ($)
Aug. 23, 2024
$ / shares
shares
Jul. 23, 2024
May 31, 2024
USD ($)
$ / shares
shares
Mar. 28, 2024
USD ($)
Dec. 21, 2022
USD ($)
Aug. 31, 2022
USD ($)
Apr. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
Apr. 21, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2025
₪ / shares
Jun. 30, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
₪ / shares
Dec. 31, 2024
USD ($)
shares
Aug. 23, 2023
shares
Disclosure of detailed information about business combination [line items]                                                    
Operating loss                               $ 6,098 $ 9,404 [1]                  
Net operating cash outflows                               (7,483) (9,565)                  
Accumulated deficit                                             $ (281,121)   $ (274,071)  
Ordinary shares issued | shares                                             8,714,230   6,514,589  
Ordinary shares per share | ₪ / shares                                           ₪ 0.2   ₪ 0.2    
Gross proceeds from ordinary shares                               4,283 $ 86                  
Total consideration                             $ 3,464                      
Aggregate offering price                                   $ 3 $ 695 $ 22 $ 2,600          
Reverse share split ratio               1-for-10                                    
Amount from redeem SAFE       $ 10,000                                            
Subsequent Events [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Total consideration $ 18,714                                                  
Definitive Agreement [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Ordinary shares issued | shares             265,000                                      
Pre-funded warrants | shares             1,427,308                                      
Pre-funded warrant per share | $ / shares             $ 0.0001                                      
Biomica [Member] | Definitive Agreement [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Proportion of ownership interest in subsidiary                     67.00%                              
ICL Group [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Total consideration                             $ 15,250                      
Amount of investment under collaboration agreement                       $ 10,000                            
ICL Group [Member] | Subsequent Events [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Gross proceeds from ordinary shares                               4,415                    
Amount from redeem SAFE $ 10,000                                                  
Shanghai Healthcare Capital [Member] | Biomica [Member] | Definitive Agreement [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Investments in subsidiaries reported in separate financial statements                     $ 10,000                              
Total Amount Of Certain Convertible Loans                     10,000                              
Amount of investment in financing round                     $ 20,000                              
Proportion of ownership interest in subsidiary                     20.00%                              
ATM offering [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Ordinary shares issued | shares                 10,000                                  
Sell price per share | $ / shares                                             $ 2.31      
Gross proceeds from ordinary shares                 $ 85             4,415                    
Aggregate offering price           $ 4,500       $ 7,300           $ 1,913,650                    
Weighted average share price | $ / shares                 $ 8.5                                  
Series A Ordinary Warrant [Member] | Definitive Agreement [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Exercise price per warrant | $ / shares             3.55                                      
Number of ordinary shares sold | shares                                                   1,692,308
Series B Ordinary Warrant [Member] | Definitive Agreement [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Exercise price per warrant | $ / shares             3.55             $ 1,146,308                        
Aggregate offering price                         $ 281,000 $ 1,146,308                        
Series A And B Ordinary Warrant [Member] | Definitive Agreement [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Gross proceeds from ordinary shares                 $ 5,500                                  
Purchase price per share | $ / shares             $ 3.25                                      
Lavie Bio Ltd [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Investments in subsidiaries reported in separate financial statements     $ 10,000                                              
Ownership percentage held by other entity in subsidiary     27.84%   27.84%                                          
Lavie Bio Ltd [Member] | ICL Group [Member] | Subsequent Events [Member]                                                    
Disclosure of detailed information about business combination [line items]                                                    
Amount from redeem SAFE   $ 10,000                                                
[1] Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.